CurrentBlue KCPolicy POL-PP-220

Bariatrics and Vitamin B12 Injections

Defines coverage and reimbursement rules for Vitamin B12 testing and injections relating to bariatric patients and general screening, and specifies billing rules during the global surgical period. Affects professional and facility providers and multiple Blue KC lines of business.

Policy Summary

PayerBlue KC

PolicyBariatrics and Vitamin B12 Injections

Policy CodePolicy POL-PP-220

Change TypeNo material change

Effective DateDec 1, 2025

Next Review DateDec 1, 2026

Key ActionDuring the 90-day bariatric global period, Vitamin B12 (J3420) and administration (96372) are included in the global fee and are not separately billable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

90-dayglobal period for bariatric surgery (B12 and injection included)

3 monthsearliest interval for repeat testing after initiation of B12 therapy

Version 05policy version

PROF & FACprovider/entity impacted

Coverage Criteria and Billing Rules

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria and billing rules

Covered, non‑covered, and billing rules for Vitamin B12 screening, diagnostic testing, and injections — applied as written below.

Screening for Vitamin B12 deficiency in healthy, asymptomatic individuals is non-covered.

Homocysteine testing for the confirmation of vitamin B12 deficiency is non-covered.

Holotranscobalamin testing for screening, testing, or confirmation of vitamin B12 deficiency is non-covered.

Methylmalonic acid testing is allowed to confirm vitamin B12 deficiency in asymptomatic high-risk patients with low-normal vitamin B12 or when deficiency is suspected but serum vitamin B12 is normal or low-normal.

When a Vitamin B12 screening reveals a deficiency, any subsequent testing should be performed no sooner than 3 months after initiation of therapy for that deficiency.

Repeat testing interval: no sooner than 3 months after therapy initiation.

Bariatric-specific allowance

Screening and injections for Vitamin B12 deficiency may be allowed for patients who have undergone bariatric procedures (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion/duodenal switch) when performed outside of the global period.
During the 90-day bariatric global period, Vitamin B12 (J3420) and administration of the injection (96372) are included in the global fee and are not separately billable.
Bariatric global period = 90 days; J3420 and 96372 bundled into global surgical package.

B12 injections include time for pre-service evaluation; submission of an E/M (99202–99215) is allowed only if the E/M is significant, separately identifiable, and exceeds the pre-service evaluation inherent to the injection.

Relevant Codes and Testing Intervals

Relevant lab and injection codesmixed

82607	Cyanocobalamin (Vitamin B-12)
82608	Cyanocobalamin (Vitamin B-12); unsaturated binding capacity
83921	Organic acid, single, quantitative
83090	Homocysteine
J3425	Injection, hydroxocobalamin, IM, 10 mcg
J3420	Injection, vitamin B-12 cyanocobalamin, up to 1,000 mcg
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

inv-03: Repeat testing after therapy initiation — No sooner than 3 months

Repeat testing intervalWhen B12 screening reveals deficiency, any subsequent testing should be performed no sooner than 3 months after initiation of therapy.

ContextApplies to follow-up diagnostic testing after initiation of Vitamin B12 therapy for deficiency.

PurposeEnsures adequate time for therapeutic response before repeat measurement to avoid premature retesting.

Billing Considerations and Prior Authorization

Prior Authorization

Prior Authorization / Billing Considerations

Prior authorization is required when applicable by member benefit; verify coverage and obtain prior authorization before providing services not explicitly covered. B12 injections include time for pre-service evaluation. Submit an E/M (99202-99215) only when the E/M service is significant, separately identifiable, and clearly exceeds the pre-service evaluation inherent to the injection.

Affected codes: J3420 (Vitamin B12, cyanocobalamin, per 1,000 mcg) — injected product
Affected codes: 96372 (Therapeutic, prophylactic, or diagnostic injection) — administration
Affected codes: 99202-99215 (Office/outpatient E/M) — bill only if significant, separately identifiable service beyond pre-service evaluation
Note: Confirm whether member benefits require prior authorization for B12 laboratory testing or injections
Billing rule: Do not bill J3420 and 96372 separately during the 90-day global period following bariatric surgery (e.g., Roux-en-Y, gastric bypass, sleeve gastrectomy, biliopancreatic diversion/duodenal switch)

Key Definitions

inv-05: Bariatric — definition for bariatric treatments, commonly surgery

Definition'Bariatric' refers to treatments, most commonly surgery, for severe obesity that help people lose weight by altering the digestive system.

Common proceduresExamples include Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion/duodenal switch (see policy for context).

RelevanceBariatric patients may have specific coverage and billing rules for Vitamin B12 screening and injections, particularly related to the surgical global period.

inv-06: Vitamin B12 — definition and clinical role

DefinitionVitamin B12 (cobalamin) is an essential nutrient that supports healthy nerve function, red blood cell formation, and DNA synthesis; it must be obtained from food or supplements.

SourcesFound naturally in animal products such as meat, eggs, and dairy; the body cannot synthesize it.

Clinical roleUsed in screening and diagnostic evaluation of deficiency; injections and testing have specific coverage and billing considerations within the policy.